NCT05963490View on ClinicalTrials.gov

Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

April 25, 2023

Primary Completion Date

April 25, 2025

Study Completion Date

April 25, 2026

Conditions
Microsatellite Stable Metastatic Colorectal Cancer
Interventions
DRUG

Regorafenib

Regorafenib 120 mg orally once daily on days 1-21 of each 28 days cycle.

DRUG

Toripalimab

240 mg intravenously every 3 weeks

RADIATION

Radiotherapy

hypofractionated radiotherapy (5 fractions of 4-12Gy) and low-dose radiotherapy (5 fractions of 0.5-2Gy).

DRUG

Regorafenib

Regorafenib 80mg orally once daily on days 1-21 of each 28 days cycle.

Trial Locations (1)

Unknown

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER